SCHEMBL300573

SCHEMBL300573

CC[C@](C)(C(=O)O)C1CN(C2=Nc3cc(Cl)ccc3Oc3ccccc32)CCN1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 8/20 0.59
DRD4 P21917 4/20 0.52
DRD2 P14416 3/20 0.52
HTR2C P28335 5/20 0.52
HTR2A P28223 9/20 0.50
HRH1 P35367 7/20 0.50
ADRA2A P08913 4/20 0.50
HRH2 P25021 3/20 0.50
HTR1A P08908 3/20 0.50
MEN1 O00255 2/20 0.50
LMNA P02545 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50
PMP22 Q01453 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
ADRB2 P07550 2/20 0.50
CHRM2 P08172 2/20 0.50
CHRM4 P08173 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL300592 1.00 HRH4 (0.59) HRH4DRD4DRD2HTR2CHTR2A
SCHEMBL120387 1.00 HRH4 (0.59) HRH4DRD4DRD2HTR2CHTR2A
SCHEMBL300927 1.00 HRH4 (0.59) HRH4DRD4DRD2HTR2CHTR2A
SCHEMBL300570 1.00 HRH4 (0.59) HRH4DRD4DRD2HTR2CHTR2A
SCHEMBL300241 1.00 HRH4 (0.59) HRH4DRD4DRD2HTR2CHTR2A
SCHEMBL300314 1.00 HRH4 (0.59) HRH4DRD4DRD2HTR2CHTR2A
SCHEMBL300298 0.94 HRH4 (0.60) HRH4DRD4DRD2HTR2CHTR2A
SCHEMBL300070 0.94 HRH4 (0.60) HRH4DRD4DRD2HTR2CHTR2A
SCHEMBL300213 0.94 HRH4 (0.60) HRH4DRD4DRD2HTR2CHTR2A
SCHEMBL301315 0.94 HRH1 (0.58) HRH4DRD4DRD2HTR2CHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137180-B1 DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS ARYX THERAPEUTICS INC (US) 2012-03-07 EP claimed
US-8093237-B2 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction ARYX THERAPEUTICS, INC. (US) 2012-01-10 US claimed